Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation.
Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation.
复制标题
DOI：
10.1002/jimd.12238
复制
发表时间：
2020-09
影响因子：
4.2
通讯作者：
Saba JD
中科院分区：
文献类型：
--
作者：
Zhao P;Liu ID;Hodgin JB;Benke PI;Selva J;Torta F;Wenk MR;Endrizzi JA;West O;Ou W;Tang E;Goh DL;Tay SK;Yap HK;Loh A;Weaver N;Sullivan B;Larson A;Cooper MA;Alhasan K;Alangari AA;Salim S;Gumus E;Chen K;Zenker M;Hildebrandt F;Saba JD
1-磷酸鞘氨醇 (S1P) 裂解酶是一种维生素 B6 依赖性酶，可在鞘脂代谢的最后一步降解 1-磷酸鞘氨醇。 2017 年，一种新的遗传性疾病被描述为由 SGPL1 突变引起，SGPL1 编码磷酸鞘氨醇裂解酶 (SPL)。这种情况称为 SPL 不足综合征 (SPLIS) 或 14 型肾病综合征 (NPHS14)。 SPLIS 患者表现出淋巴细胞减少、肾病、肾上腺功能不全和/或神经系统缺陷。目前尚无 SPLIS 靶向治疗的报道。维生素 B6 补充剂对某些涉及 B6 依赖性酶的遗传性疾病具有治疗活性，这一发现很大程度上归因于维生素的伴侣功能。我们研究了维生素 B6 补充剂是否对 SPLIS 患者有效。我们回顾性监测补充 B6 的患者疾病生物标志物的反应，并测量 B6 治疗的患者来源的成纤维细胞中的 SPL 活性和鞘脂。在两名患者中，疾病生物标志物对维生素 B6 补充剂有反应。 B6 导致 S1P 丰度和活性水平增加，鞘脂减少。一名有反应的患者是 SPL R222Q 变异纯合子，该变异存在于近 30% 的 SPLIS 患者中。分子模型表明该变体扭曲了二聚体界面，这可以通过补充辅因子来克服。我们展示了第一个潜在的 SPLIS 靶向治疗，并表明 30% 的 SPLIS 患者可能对辅因子补充有反应。
Sphingosine-1-phosphate (S1P) lyase is a vitamin B6-dependent enzyme that degrades sphingosine-1-phosphate in the final step of sphingolipid metabolism. In 2017, a new inherited disorder was described caused by mutations in SGPL1, which encodes sphingosine phosphate lyase (SPL). This condition is referred to as SPL insufficiency syndrome (SPLIS) or alternatively as nephrotic syndrome type 14 (NPHS14). Patients with SPLIS exhibit lymphopenia, nephrosis, adrenal insufficiency, and/or neurological defects. No targeted therapy for SPLIS has been reported. Vitamin B6 supplementation has therapeutic activity in some genetic diseases involving B6-dependent enzymes, a finding ascribed largely to the vitamin’s chaperone function. We investigated whether B6 supplementation might have activity in SPLIS patients. We retrospectively monitored responses of disease biomarkers in patients supplemented with B6 and measured SPL activity and sphingolipids in B6-treated patient-derived fibroblasts. In two patients, disease biomarkers responded to B6 supplementation. S1P abundance and activity levels increased and sphingolipids decreased in response to B6. One responsive patient is homozygous for an SPL R222Q variant present in almost 30% of SPLIS patients. Molecular modeling suggests the variant distorts the dimer interface which could be overcome by cofactor supplementation. We demonstrate the first potential targeted therapy for SPLIS and suggest that 30% of SPLIS patients might respond to cofactor supplementation.
登录
查看更多内容
SGPL1中的变体引起的肾病综合征和肾上腺功能不全。
影响因子：
4.6
作者：
Linhares ND;Arantes RR;Araujo SA;Pena SDJ
通讯作者：
Pena SDJ
DOI：
10.1172/jci90171
发表时间：
2017-03-01
期刊：
The Journal of clinical investigation
影响因子：
--
作者：
Prasad R;Hadjidemetriou I;Maharaj A;Meimaridou E;Buonocore F;Saleem M;Hurcombe J;Bierzynska A;Barbagelata E;Bergadá I;Cassinelli H;Das U;Krone R;Hacihamdioglu B;Sari E;Yesilkaya E;Storr HL;Clemente M;Fernandez-Cancio M;Camats N;Ram N;Achermann JC;Van Veldhoven PP;Guasti L;Braslavsky D;Guran T;Metherell LA
通讯作者：
Metherell LA
影响因子：
3.5
作者：
HU, FL;GU, Z;SHIH, VE
通讯作者：
SHIH, VE
影响因子：
9.9
作者：
Atkinson, Derek;Glumac, Jelena Nikodinovic;Jordanova, Albena
通讯作者：
Jordanova, Albena
DOI：
10.1111/ajt.12706
发表时间：
2014-06
期刊：
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子：
--
作者：
Lorenz EC;Lieske JC;Seide BM;Meek AM;Olson JB;Bergstralh EJ;Milliner DS
通讯作者：
Milliner DS